The clinical efficacy and safety of micafungin-itraconazole combination therapy in patients with pulmonary aspergilloma

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Masaki FujitaYoichi Nakanishi

Abstract

In spite of recent advances in chemotherapy, the treatment of pulmonary aspergilloma remains unsatisfactory. To evaluate the clinical efficacy and safety of combination therapy for pulmonary aspergilloma, we conducted a multi-institutional prospective study using micafungin (MCFG) and itraconazole (ITCZ). Adult patients who fulfilled the criteria for pulmonary aspergilloma were enrolled in this study. After patient consent had been obtained, intravenous MCFG 150 mg/day and an oral capsule of ITCZ 200 mg/day were administered for at least 1 month. The primary endpoint was the response assessed using an algorithm that incorporated the levels of improvement by evaluating clinical symptoms and signs, mycological and serological tests, and diagnostic imaging. A total of 17 patients were enrolled from three facilities. The response rate to the combination therapy was 58.8% (10/17). The long-term control in the group of patients who responded to treatment was better than that in the group of patients who did not respond. Adverse events occurred in 6 of the 17 patients (35.3%), but there were no severe adverse events. MCFG-ITCZ combination therapy appeared to be relatively safe and effective in patients with pulmonary aspergilloma.

References

Jul 31, 2001·FEMS Immunology and Medical Microbiology·C P SemighiniG H Goldman
Feb 26, 2004·Antimicrobial Agents and Chemotherapy·Melissa D JohnsonJohn H Rex
Aug 4, 2004·Scandinavian Journal of Infectious Diseases·Shigeru KohnoHideo Ikemoto
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kieren A MarrLawrence Corey
Oct 16, 2004·Expert Review of Anti-infective Therapy·Yasuhito Higashiyama, Shigeru Kohno
Jul 16, 2005·Current Opinion in Microbiology·Fredj Tekaia, Jean-Paul Latgé
Apr 25, 2006·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·Masaki OkamotoKazuhiro Hatta
Jun 29, 2006·Current Opinion in Infectious Diseases·Karl V Clemons, David A Stevens
Jan 24, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Arlo UptonKieren A Marr
May 17, 2007·Current Medicinal Chemistry·Fumiaki IkedaYoshiyasu Aoki
Jun 15, 2007·Bone Marrow Transplantation·M D Johnson, J R Perfect
Aug 28, 2007·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hiroshi OuchiYoichi Nakanishi
Jul 22, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Brahm H SegalBen E De Pauw
Nov 6, 2008·Transplant Infectious Disease : an Official Journal of the Transplantation Society·D P KontoyiannisK A Marr

❮ Previous
Next ❯

Citations

Feb 18, 2016·Respiratory Investigation·Koichi Izumikawa
Feb 1, 2014·The Journal of Infection·D A EnochJ A Karas
Feb 26, 2016·Chest·Cendrine GodetUNKNOWN ACHROSCAN Study Group
Jul 27, 2017·The Journal of Pharmacy and Pharmacology·Akash Patil, Soumyajit Majumdar
Jul 2, 2014·Antimicrobial Agents and Chemotherapy·Yali LiRuoyu Li
Apr 7, 2020·Expert Review of Respiratory Medicine·Inderpaul Singh SehgalRitesh Agarwal
Oct 24, 2019·BMJ : British Medical Journal·Daniel A Culver, Marc A Judson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Related Papers

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Koichiro YoshidaYoshihito Niki
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Hiroshi OuchiYoichi Nakanishi
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Koichiro YoshidaYoshihito Niki
© 2022 Meta ULC. All rights reserved